Shots:

• The P-III study involves assessing of Revatio (IV) + inhaled nitric oxide (iNO) vs iNO as monothx. in newborn babies with persistent pulmonary hypertension
• The P-III study results did not meet its 1EPs i.e- reduction in the treatment failure rate or time on iNO. The study was part of an EU Pediatric Investigational Plan (PIP)
• Revatio is a PDE-5 inhibitor and has received EC’s approval in Oct’2005 for the treatment of pulmonary arterial hypertension classified as WHO functional class II and III- to improve exercise capacity in adults. Additionally- it is approved in the EU & Japan for pediatric PAH

Click here to read full press release/ article | Ref: Pfizer | Image: Economic times